Another Five Days of Biotech Stocks GRINDING Along

Recap - No one has the exact answer, but Mr. King’s post-JP Morgan musings from earlier this year seem relevant yet again. As of Friday’s close, the S&P 500 is actually down year-to-date, while the biotechnology sector is up an impressive 14%, as measured by the IBB. The two have clearly diverged, and it almost seems that investors are fleeing to biotechnology for safety. That’s quite a departure from years past.

Read Now

Our Weekly Healthcare Roundup

Recap - This week at PropThink we published Mr. Deryugin's assessment of a recently released draft bill, the 21st Century Cures Act, that could profoundly change the way many drugs are evaluated and approved by the FDA.

Read Now